New Indian Public Shareholding Proposal Stumps Pharma
Executive Summary
A proposal to increase the minimum public shareholding in listed firms in India, if implemented, is expected to impact the subsidiaries of GlaxoSmithKline, Novartis and AstraZeneca in the country, as well as local firms like Cadila Healthcare. Some of the foreign firms may well consider delisting